3 results
Approved WMORecruiting
To test the clinical efficacy of vibrating socks, a new tactile cueing device, for the management of FOG in patients with PD.
Approved WMOPending
The primary objective is to determine the safety, tolerability, dose-limiting toxicities (DLTs), and maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) of BMS-986178 administered alone or in combination with nivolumab and/or ipilimumab in…
Approved WMORecruiting
To evaluate the usability of vibrating socks as a home-based tactile cueing device in PD.